Ignite Creation Date:
2025-12-24 @ 7:10 PM
Ignite Modification Date:
2025-12-28 @ 4:24 AM
Study NCT ID:
NCT00701103
Status:
COMPLETED
Last Update Posted:
2018-08-08
First Post:
2008-06-17
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-01-12
Start Date Type:
ACTUAL
Primary Completion Date:
2009-12-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2009-12-01
Completion Date Type:
ACTUAL
First Submit Date:
2008-06-17
First Submit QC Date:
None
Study First Post Date:
2008-06-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-01-31
Results First Submit QC Date:
None
Results First Post Date:
2017-03-21
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-07-12
Last Update Post Date:
2018-08-08
Last Update Post Date Type:
ACTUAL